Endothelins as cardiovascular peptides

被引:55
作者
Levin, ER [1 ]
机构
[1] UNIV CALIF IRVINE, DEPT MED & PHARMACOL, IRVINE, CA 92717 USA
关键词
endothelin; receptors; signaling;
D O I
10.1159/000169004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The normal functional state of the vasculature and the events leading to the development of significant arterial disease involve the interaction of important vasoactive substances, which play important modulating or initiating roles in the development of hypertension and arteriosclerosis. Three endothelins have now been identified, of which ET-1 is the best characterized. ET-1 is produced by epithelial, mesangial, neuronal and glial, and liver cells, and is the most potent vasoconstrictor yet found. Each endothelin is derived from a different gene on separate chromosomes, and each binds to at least 2 types of receptor. The plasma half-life of ET-1 is about 7 min, and this provides a rapid mechanism for adjusting vascular resistance or blood pressure. The actions of endothelin are mediated through several pathways of postreceptor signaling, including activation of the mitogen-activated protein kinase cascade, which give rise to its growth-stimulating properties. Secretion of ET-1 from cultured endothelial cells is stimulated by a wide range of substances, and is inhibited by some prostaglandins. Endothelin in turn stimulates secretion of nitric oxide, arginine vasopressin and atrial natriuretic peptide, and participates in the hormonal control of salt and water balance. Hypoxia and ischemia augment ET-1 secretion, as does insulin, and this could play a role in the accelerated vascular disease of diabetes. ET-1 also causes bronchoconstriction and has been implicated in the development of acute asthma, primary pulmonary hypertension and pulmonary fibrosis. Its role in hypertension is still debatable, though most of the manifestations of congestive heart failure can theoretically be explained by the actions of ET-1. Endothelin also has extensive renovascular and parenchymal effects in the kidney. It is hoped that a fuller understanding of the role of endothelins in normal or pathologic vasculature will lead to effective therapy based on antagonism or augmentation of specific functions.
引用
收藏
页码:246 / 251
页数:6
相关论文
共 63 条
[1]  
ANGGARD EE, 1990, BLOOD VESSELS, V27, P269
[2]   CLONING AND EXPRESSION OF A CDNA-ENCODING AN ENDOTHELIN RECEPTOR [J].
ARAI, H ;
HORI, S ;
ARAMORI, I ;
OHKUBO, H ;
NAKANISHI, S .
NATURE, 1990, 348 (6303) :730-732
[3]  
ARAMORI I, 1992, J BIOL CHEM, V267, P12468
[4]   RELEASE OF ENDOTHELIN FROM THE PORCINE AORTA - INHIBITION BY ENDOTHELIUM-DERIVED NITRIC-OXIDE [J].
BOULANGER, C ;
LUSCHER, TF .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (02) :587-590
[5]   PRELIMINARY EVIDENCE FOR HOMEOSTATIC MECHANISM REGULATING ENDOTHELIN PRODUCTION IN PREECLAMPSIA [J].
BRANCH, DW ;
DUDLEY, DJ ;
MITCHELL, MD .
LANCET, 1991, 337 (8747) :943-945
[6]   EFFECT OF AN ENDOTHELIN-RECEPTOR ANTAGONIST ON ISCHEMIC ACUTE-RENAL-FAILURE [J].
CHAN, L ;
CHITTINANDANA, A ;
SHAPIRO, JI ;
SHANLEY, PF ;
SCHRIER, RW .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (01) :F135-F138
[7]   PATHOPHYSIOLOGICAL ROLE OF ENDOTHELIN REVEALED BY THE 1ST ORALLY-ACTIVE ENDOTHELIN RECEPTOR ANTAGONIST [J].
CLOZEL, M ;
BREU, V ;
BURRI, K ;
CASSAL, JM ;
FISCHLI, W ;
GRAY, GA ;
HIRTH, G ;
LOFFLER, BM ;
MULLER, M ;
NEIDHART, W ;
RAMUZ, H .
NATURE, 1993, 365 (6448) :759-761
[8]  
DANTHULURI NR, 1990, J PHARMACOL EXP THER, V254, P393
[9]   ENDOTHELIN-3 STIMULATES PRODUCTION OF ENDOTHELIUM-DERIVED NITRIC-OXIDE VIA PHOSPHOINOSITIDE BREAKDOWN [J].
EMORI, T ;
HIRATA, Y ;
KANNO, K ;
OHTA, K ;
EGUCHI, S ;
IMAI, T ;
SHICHIRI, M ;
MARUMO, F .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 174 (01) :228-235
[10]   VASOCONSTRICTIVE RESPONSES ELICITED BY ENDOTHELIN IN BOVINE CEREBRAL-ARTERIES [J].
ENCABO, A ;
FERRER, M ;
MARIN, J ;
VILLAMOR, J ;
BALFAGON, G .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1992, 23 (02) :263-267